On October 23, 2018, Stoke Therapeutics, Inc. closed the transaction. The company received $89,999,993.1072 in series B round of funding led by new investor RTW Investments, LLC . The transaction also included participation from new investors RA Capital Management, LLC, Cormorant Asset Management, LLC, Cormorant Asset Management, LLC, Perceptive Advisors LLC, Redmile Group, LLC, funds managed by Janus Henderson Investors, Sphera Funds Management Ltd, Alexandria Venture Investments, LLC, and returning investor Apple Tree Partners. As part of the transaction, Roderick Wong from RTW Investments, LLC, Matthew Hammond from RA Capital Management, LLC, and Bihua Chen from Cormorant Asset Management, LLC will join the board of the company as observers.